Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age
Authors Karagiannis D, Kontadakis GA, Kaprinis K, Giarmoukakis A, Georgalas I, Parikakis EA, Tsilimbaris MK
Received 20 February 2017
Accepted for publication 19 April 2017
Published 22 June 2017 Volume 2017:11 Pages 1197—1201
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr Scott Fraser
Dimitrios Karagiannis,1 Georgios A Kontadakis,1,2 Konstantinos Kaprinis,1 Athanassios Giarmoukakis,2 lias Georgalas,3 Efstratios A Parikakis,1 Miltiadis K Tsilimbaris2
1Ophthalmiatreio Eye Hospital of Athens, Athens, Greece; 2Department of Ophthalmology, University Hospital of Heraklion, University of Crete, Heraklio, Greece; 3Department of Ophthalmology, University of Athens, Athens, Greece
Purpose: The aim of this study was to explore the role of age as a prognostic factor for the outcome of myopic choroidal neovascularization (CNV) treatment with intravitreal ranibizumab injections.
Methods: A retrospective review of charts of patients treated with intravitreal injections of ranibizumab for the treatment of myopic CNV was done. Patients with other ophthalmic disease were excluded. Patients were followed for at least 2 years. The correlation between age and the change in visual acuity and the number of injections during treatment was investigated.
Results: Age of the patients was significantly correlated with the number of injections that the patients received (Pearson’s r=0.585, P=0.005). Also, it was significantly correlated with improvement in corrected distance visual acuity, defined as the difference between final and initial LogMAR corrected distance visual acuity (Pearson’s r=0.614, P=0.003).
Conclusion: Age significantly affects the visual outcome of myopic CNV treatment with ranibizumab. Younger patients in our study needed fewer intravitreal injections and achieved a more significant improvement in vision.
Keywords: myopic choroidal neovascularization, intravitreal injection, ranibizumab, pathologic myopia
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]